Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Obesity Drugs Panel To Mull Whether Products Without CV Signal Need Outcomes Trial

This article was originally published in The Pink Sheet Daily

Executive Summary

The Endocrinologic and Metabolic Drugs Advisory Committee also will evaluate methods for collecting cardiovascular risk information for obesity drugs with a CV safety signal, as FDA seeks input on when and how sponsors should evaluate their products.

Advertisement

Related Content

FDA Clears Belviq With Post Hoc Finding Of Less Than Double Placebo CV Risk
CV Trials For Obesity Drugs Won’t Be Conducive To Easy Interpretation, Panel Indicates
Orexigen Agreement On Contrave CV Trial Hints At FDA’s Thinking On Obesity
Panel Continues To Push For Obesity CV Guidance As It Backs Contrave Approval
FDA Diabetes Guidance Encourages Enrollment Of Sicker Patients

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS073930

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel